ht-2157
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2011 (NCT01413932)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Galanin receptor 3ANTAGONIST
GALR3 antagonist
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297765 ↗
Also known as
- ht-2157
- ht-2157
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01413932 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2011 | Dart NeuroScience, LLC |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dart NeuroScience, LLC | For profit | 1 | 1 | 1 | 2011 |
1 organizations
Page 1 / 1